Efficacy of clinical whole abdominal intensity modulated radiotherapy in platinum-resistant recurrent epithelial ovarian cancer and its influence on the expression of tumor markers
Objective To investigate the short-term and long-term therapeutic efficacy of whole abdominal intensity modulated radiotherapy in patients with recurrent epithelial ovarian cancer(REOC)and its impact on the levels of car-bohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and carbohydrate antigen 153(CA153).Methods Retrospective cohort study,selected the clinical data of 101 patients with epithelial ovarian cancer treated in the First Affiliated Hospital of Zhengzhou University from June 2020 to June 2022 were retrospectively analyzed,and the patients were divided into different treatment plans after recurrence.52 patients in the control group received chemother-apy alone,and 49 patients in the study group received whole abdominal intensity modulated radiotherapy based on the control group.The adverse reactions,tumor markers,long-term efficacy,and short-term efficacy of the two groups were compared.Results The disease control rate of the study group(75.51％)was higher than that of the control group(55.77％),and the difference was statistically significant(P＜0.05);progression-free survival(PFS)and overall survival(OS)of the study group were longer than those of the control group,and the differences were statistical-ly significant(P＜0.05);after treatment,the levels of tumor markers such as CA125,CEA and CA153 in the study group[(36.49±4.61)U/mL,(4.54±1.34)U/mL,(30.12±3.21)U/mL]were significantly lower than those in the control group(58.46±6.82)U/mL,(8.42±1.93)U/mL,(42.16±6.28)U/mL],and the difference was sta-tistically significant(P＜0.05);there was no significant difference in the incidence of adverse reactions between the two groups(26.92％vs 36.73％)(P＞0.05).Conclusion Whole abdominal intensity modulated radiotherapy can down-regulate the expression of tumor markers,improve the short-term efficacy,and prolong the survival time of pa-tients with platinum-resistant REOC without increasing adverse reactions.
NETL
NSTL
万方数据
